An integrated general practice and pharmacy-based intervention to promote the prescription and use of appropriate preventive medications among individuals at high cardiovascular risk.



Extensive evidence demonstrates the benefits of a number of drugs for the prevention of cardiovascular disease (CVD) events, particularly in those at high risk. However, there are substantial evidence-practice gaps in Australian primary healthcare settings.

The study tested an integrated intervention combining three evidence based approaches:

  1. Point-of-care electronic decision support in general practice;
  2. Availability of CVD polypills (fixed dose-combination of generic blood pressure (BP) lowering, lipid modifying ± and antiplatelet drugs);
  3. A pharmacy-led medication adherence intervention will increase prescription and long-term use of recommended medications, leading to improvements in CVD risk factor levels

These strategies were systematically evaluated in a pragmatic cluster RCT in Australian General Practice and Pharmacy pairs with the primary outcome being the proportion of high-risk patients who were not on full treatment at baseline achieving recommended target BP and LDL-C target levels at study end. The final data collection took place in late 2019 and the study results will be analysed and published in 2020.


The study is being conducted by Monash University and the George Institute for Global Health, NSW and funded by the NHMRC.

Trial Registration